focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK detects S.African coronavirus variant in people with no travel links

Mon, 01st Feb 2021 12:28

(Adds government statement, details)

LONDON, Feb 1 (Reuters) - Eleven people in different regions
have tested positive for the South African coronavirus variant
without having any links to people who have travelled recently,
prompting mass testing in the areas to contain the outbreak.

The government said on Monday the cases were now
self-isolating and robust contact tracing had taken place to
trace their contacts and ask them to self-isolate.

Residents in eight postcodes - three in London; two in the
south east and one in the West Midlands, east of England, and
the North West - would now be tested for the new coronavirus
whether they are showing any symptoms or not under what is known
as "surge testing" it said.

"Every person over 16 living in these locations is strongly
encouraged to take a Covid test this week, whether they are
showing symptoms or not," the government said in a statement.

The government said in January it had detected cases of both
the South African and Brazilian variants, but all were linked to
travel.

In total, Public Health England said it had identified 105
cases of the South African variant since Dec 22.

All viruses mutate frequently, and scientists have
identified several variants of the novel coronavirus found to be
more transmissible than the original strain.

The emergence of more infectious variants has raised
questions over whether vaccines will prove as effective in
containing them.

Scientists have said the South African variant appears to be
more transmissible, but there is no evidence it causes more
severe disease. But several laboratory studies have found that
it reduces vaccine and antibody therapy efficacy.

Clinical trial data on two COVID-19 vaccines - from Novavax
and Johnson & Johnson - released on Saturday showed they had
less ability to protect against the illness caused by the South
African variant.

But the Surrey Local Resilience Forum said there was no
evidence the regulated vaccine would not protect against it. The
Oxford-AstraZeneca and Pfizer-BioNTech vaccines are being rolled
out across Britain.

(Reporting by Kate Holton, Michael Holden and Paul Sandle,
editing by Estelle Shirbon and Timothy Heritage)

More News
Today 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.